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1. Introduction  
Drug-induced encephalopathy is a disease entity often caused by impaired cerebral 
metabolism that is not attributed to structural brain lesions. However, some drug-induced 
encephalopathies can develop structural lesions and share other underlying 
pathophysiological mechanisms (table 2). Leading symptoms are acute or chronic 
disturbances of consciousness, brain function and personality changes with concomitant 
neurological symptoms such as asterixis, myoclonias, paresis or seizures (see table 3). 
Isoniazid-induced encephalopathy was one of the earliest descriptions of a drug-induced 
encephalopathy (Adams & White, 1965). Clinical symptoms depend on the type and 
severity of the drug-evoked encephalopathy. A well-described and frequently-reported 
drug-induced encephalopathy is valproic acid encephalopathy, first described in the late 
1970s. This acute encephalopathy was characterized by altered behaviour, worsening 
seizure control and confusion. After a reduction in the valproate acid dose, the patient’s 
symptoms resolved completely (Chadwick et al., 1979). Encephalopathies have been 
reported after consumption of several types of drugs as depicted below (table 1). 
2. Drugs  
2.1 Analgesics and anaesthesia 
Drug-induced encephalopathy was reported after morphine administered intrathecally and 
the use of propofol (Eran & Barak, 2009). Morphine has been described as having induced 
an encephalopathy characterized by a myoclonus, motor dysfunction, or vertigo (Goundrey, 
1990; Kakinohana et al., 2003). Spinal anaesthesia with hyperbaric bupivacaine lead to an 
encephalopathy that developed a few days after the drug’s administration (Ho & Chan, 
2007). A drug abuse-evoked encephalopathy was also reported after ketamine and gamma 
hydroxybutyrate (Virmani et al., 2010). Toxic encephalopathy has been described after 
intake of an acetaminophen overdose (Brusilow & Cooper, 2011).  
2.2 Antibiotics  
Drug-induced encephalopathy can occur after an intake of cefepime and metronidazole 
(Kim et al., 2011; Lin et al., 2011). The incidence of metronidazole-induced encephalopathy is 
unknown. Several studies addressed reversible brain changes caused by metronidazole 
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induced-encephalopathy (Ahmed et al., 1995), and bilateral, symmetric brain abnormalities 
have been observed in patients (Ahmed et al., 1995; Kim et al., 2011). Ceftriaxone induced a 
reversible encephalopathy in an patient treated for a urinary tract infection (Rancon-
Albuquerque et al., 2009). That encephalopathy was completely reversible. An early-onset 
encephalopathy a day and a half after linezolid therapy occurred in a male, thus clinicians 
must be aware of the potential of linezolid-induced encephalopathy, particularly in patients 
presenting risk factors (Fletcher et al., 2010). Clarithromycin has also induced an 
encephalopathy in adults characterized by symptoms appearing 1-10 days after drug intake 
and displaying clinical features ranging from delirium to non-convulsive status epilepticus 
(Bandettin di Poggio et al., 2011). Chinolones like ciprofloxacin and gemifloxacin are also 
reported to induce an encephalopathy (Rfidah et al., 1995; Barrett MJ 2009). Cephalosporine 
is reported to evoke an encephalopathy associated with a variety of electroencephalografic 
manifestations (Grill & Magati, 2008). Other cephalosporines such as cefuroxime, 
ceftazidime and cefazoline can result in an encephalopathy as well (Herishanu et al. 1988, 
Jackson et al., 1992; Ortiz et al., 1991). Cefoperazone is a cephalosporine that can cause a 
reversible encephalopathy characterized by triphasic waves in electroencephalography (Pro 
et al., 2011). Also penicillin-based antibiotics like penicillin itself, piperacillin and 
pivmecillinam caused an encephalopathy (Park-Matsumoto et al., 1996; Conway et al., 1968; 
Lokrantz et al., 2004).  
2.3 Antiviral agents 
Antiviral agents have seldom been reported to have induced an encephalopathy. As 
described in one case report, aciclovir can cause an encephalopathy. That patient had 
normal blood levels of aciclovir, and his renal function was normal ( Delluc et al., 2004).  
2.4 Antidepressants 
Antidepressants can also result in an encephalopathy. The drug amitriptyline can cause an 
encephalopathy appearing as a neuroleptic malignant syndrome or a serotonin syndrome 
spectrum disorder (Miyaoka & Kamijama, 1995).  
2.5 Anticonvulsants 
The following anticonvulsants have been reported to induce a drug-induced 
encephalopathy: carbamazepine, gabapentin, levetiracetame, lamotrigine, phenytoine, 
primidone, topiramate, valproic acid and vigabatrine (Engel et al., 1971; Bauer & Elger, 1993; 
Hennessy & Miles, 1996; Garcia-Pastor et al., 2000; Sechi et al., 2004; Siniscalchi et al., 2004; 
Cheung et al., 2005; Horvath et al., 2005; Bauer, 2008). The most studied encephalopathy is 
valproic acid encephalopathy, which was first reported in epileptic and later psychiatric 
patients (Duarte et al., 1993; Settle, 1995). Valproic acid encephalopathy is often reversible 
after a week; prolonged time courses have been rare (Bauer & Elger, 1993). Antiepileptic 
drug-induced encephalopathies represent a seldom, but important side effect of 
antiepileptic drug therapy. There is an estimated 2% incidence of combined topiramate, 
valproate acid- induced hyperammonemic encephalopathy (Cheung et al., 2005). An 
average age of 38.6 years has been reported in a long-term study of valproic acid-induced 
encephalopathy (Gerstner et al., 2007).  
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2.6 Antineoplastic drugs and chemotherapeutics 
Capecitabine is an antineoplastic drug replacing 5-Fluouracil in clinical practice. This drug 
can result in an encephalopathy with seizures even if a conventional dosis is used. No 
correlation was found between the encephalopathy development and a 
dihydropyridimidine dehydrogenase mutation (Fantini et al., 2010). Carmofur, a 5-
fluorouracil derivative that induced a subacute leukencephalopathy, revealed an unsteady 
gait and dementia (Kuzuhara et al., 1987). A rare complication associated with cisplatin 
therapy is an encephalopathy with or without seizures (Steeghs et al., 2003). In particular, 
high doses of ifofosfamide can induce an encephalopathy. Ifofosfamide can result in 
myoclonus-encephalopathy syndrome (Savica et al., 2011). A cohort study revealed a 
prevalence of 10-40% of this drug-evoked encephalopathy. Female sex, low total albumin 
and haemoglobulin levels, as well as obesity appear to be risk factors associated with a 
ifofosfamide-evoked encephalopathy (Sweiss et al., 2008). There are few reports of the CNS 
toxicity of paclitaxel. Seizures have been reported in two patients. Little or no blood brain 
barrier penetration were the result of confusion and word-finding difficulties, and the 
encephalopathy resolved itself (Perry & Warner, 1996). Vincristine is known to be an agent 
that may lead to consecutive sensory and motor dysfunction and eventually fatal 
myeloencephalopathy (Fawaz al, 1992). Cyclosporine encephalopathy has also been 
reported (Kwon et al., 2008). Methotrexate has rarely led to an acute encephalopathy, its 
incidence is 0.8% in leukaemia or lymphoma and 4.5% in osteosarcoma or malignant fibrous 
histiocytoma (Inaba et al., 2008).  
2.7 Immunosuppressants 
An encephalopathy occurred after tacrolimus administration and improved after the drug 
was discontinued. It clinically depicted a right-sided hemiplegia with responsible lesions on 
diffusion-tensor imaging and diffusion-tensor tractography of the white matter tract (Kim et 
al., 2011). Sorafenib was reported to induce an encephalopathy in a patient with hepatocellular 
carcinoma (Dogan et al., 2010). Furthermore, a posterior, reversible leukoencephalopathy 
syndrome was observed after an infusion of infliximab (Zamvar et al., 2009).  
2.8 Immunomodulators 
Intravenous immunoglobulins (IVIG) can induce an acute encephalopathy probably caused 
by a cytotoxic brain oedema (Wada et al., 2005). 
2.9 Neuroleptics and lithium 
Lithium can to lead to an encephalopathy characterized by seizures, choreiforme as well as 
parkinsonian movements with cerebellar signs. Three risk factors contribute to lithium 
toxicity: a nephrogenic diabetes insipidus, age over 50 years, and thyroid dysfunction 
(Smith et al., 2003). Haloperidol can evoke an encephalopathy characterised by an 
electroencephalography (EEG) with characteristics of toxic encephalopathy (Maxa et al., 
1997). The combination of lithium-risperidone induces an reversible encephalopathy (Boora 
& Hyatt, 2008). Two patients presented a prolonged postictal encephalopathy with 
clozapine-induced seizures (Karper et al., 1992) which lasted 63-72 hours and caused 
electroencephalographic abnormalities.  
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Drug Dosage/d Outcome after drug discontinuation Reference 
aciclovir standard 
dosis 
symptoms reversed after 72h  Delluc et al., 2004 
capecitabine 2000mg/m2 improvement of symptoms Fantini et al., 2010 
carbamazepine 1200mg symptoms and EEG normal after 2w Horvath et al., 2005 
ceftazidime 4g symptoms resolved after a few days Jackson et al., 1992 
cefoperazone 2g EEG and symptoms normal after 36h Pro et al., 2011 
dexamethasone 4mg p.o. neuroimaging improvement after 4d Irvin et al., 2007 
Duodopa 
+entacapone 
1200mg/d 
76mg/h 
100% mental status recovery after 
48h  
Manca et al., 2009 
gabapentin 900mg symptoms normalized after 4w  Sechi et al., 2004 
gemifloxacin 320mg full recovery 2d later Barrett MJ 2009 
isoretinoin 80mg full recovery 24h later  Wong et al., 2010 
IVIG 1000mg full recovery after 11d  Wada et al., 2005 
lamotrigine 400mg symptoms normalized after 4w  Sechi et al., 2004 
levetiracetame 3000mg symptoms normalized  Bauer, 2008 
lithium 400mg symptoms resolved after 1 w  Smith et al., 2003 
metronidazole 45.5g symptoms improved within 6.7d Kim et al., 2011 
morphine 0,5mg recovery after 10d Eran & Barak, 2009 
odansetron 4mg full recovery of symptoms Ritter et al., 2003 
oxcarbazepine 1800mg EEG and symptoms normalized after 
20d  
Siniscalchi et al., 
2004 
penicillin i.v. 60 Mega 
Units 
patient died Conway et al., 
1968 
phenytoine 300mg symptoms and EEG normalized Engel et al., 1971 
pivmecillinam 600mg fast symptom recovery  Lokrantz et al., 
2004  
primidone 600mg symptoms and EEG normalized after 
2 w  
Katano et al., 2002 
propofol 150mg recovery after 10d Eran & Barak, 2009 
sorafenib 400mg/2x all symptoms resolved after 5d  Dogan et al., 2010 
tacrolimus 0.1mg/kg/d imaging abnormalities normalized 
after 4m  
Kim et al., 2011 
topiramate 1400mg EEG and symptoms normalized after 
7d  
Cheung et al., 
2005 
valproic acid 2400mg improvement in EEG and symptoms Bauer & Elger, 
1993 
vigabatrine 3000mg improvement in 2w Garcia-Pastore et 
al., 2000 
d = days, EEG = Electroencephalography, h = hours, IVIG intravenous immunoglobulines, m = month, 
w = weeks, p.o. = per os 
Table 1. Drug-induced encephalopathy- clinics and outcome (not all drugs mentioned in the 
text are depicted in the table) 
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2.10 Other classes of drugs 
There are several other classes of drugs that can result in a drug-induced encephalopathy. 
For instance, baclofen [a derivative of gamma-aminobutyric acid (GABA)] caused an 
encephalopathy with severe electroencephalographic abnormalities (Kumar et al., 2010). 
Another class of drugs such as duodopa (a combination of levodopa and carbidopa) has 
induced a reversible encephalopathy in Parkinson´s disease. An intermittent multifocal 
myoclonus was observed, and neurologic examination revealed a flaccid tetraparesis 
(Manca et al., 2009). An inadvertent injection of gadolinium (solutions of chelated organic 
gadolinium complexes) can result in grand mal seizures and mental changes due to an 
encephalopathy (Kapoor et al., 2010). This gadolinium encephalopathy probably occurred 
due to the inadvertent simultaneous entry of gadolinium and blood into the subarachnoid 
space. This case highlights the importance of using only a small amount of gadolinium. 
Agents like isoretinoin (medication in the therapy of Acne) may induce an encephalopathy 
with myoclonic jerks and confusion (Wong et al., 2010). Ondansetron (a 5-HT 3 receptor 
antagonist used mainly as an antiemetic drug) can produce a multifocal encephalopathy 
depicted by a transient pyramidal and extrapyramidal dysfunction with Babinski signs, 
oculogyric crisis, oromandibular and limb dystonia. The symptoms resolved after hours. 
Anaesthesiologists must take special care when administering ondansetrone therapy 
because of this rare complication and the severe clinical manifestation reflecting transient 
structural brain damage that however results in a full resolution of neurological symptoms. 
Sulfasalazine is a drug used primarily as an anti-inflammatory agent in the treatment of 
inflammatory bowel disease and rheumatoid arthritis. It has caused an encephalopathy 
characterised by cerebrospinal fluid with a high protein level (Mut et al., 2008).  
3. Pathophysiological mechanisms 
The underlying causes of a drug-induced encephalopathy are not yet fully understood. 
Several mechanisms of drug-induced encephalopathy are discussed below (table 3). 
3.1 Cytotoxic and neurotoxic effects 
There are several pharmaceutical cytotoxic and neurotoxic side effects that can cause an 
encephalopathy. A rise in the glutamine and glutamate complex peak in MR spectroscopy 
suggests for example an exitotoxic injury in the neurons and astrocytes in an acute IVIG-
induced encephalopathy (Wada et al., 2005), and it is one possible mechanism inducing 
neurotoxicity.  
3.2 Electrolytic disturbances 
There are electrolytic disturbances such as a hypo-or hypernatremia that can promote drug-
induced encephalopathy. Hyponatremia may be a side effect of drugs such as oxcarbazepine 
or diuretics. Severe hyponatremia is commonly caused by the syndrome of inappropriate 
antidiuresis (SIADH), which can also be induced by drugs like cyclophosphamide, vincristine, 
vinblastine, thiothixene, thioridazine, haloperidol, monoamine oxidase inhibitors, tricyclic 
antidepressants, selective serotonin reuptake inhibitors and bromocripitine (Esposito et al., 
2011). Hypopotassemia plays a role in the pathogenesis of convulsions and the high rate of 
mortality in theophylline encephalopathy (Suarez Ortega et al., 1995). 
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3.3 Hepatic enzyme interactions and hyperammonemia  
Valproic acid can inhibit differential enzymes of the urea cycle, inducing a 
hyperammonemia (Sechi et al 2004, Treem et al., 1994). Moreover, there is the potential of 
damage on an enzymatic level that can lead to hyperammonemia: (1) carbamylphosphat 
synthetase-, (2) ornithin-transcarbamylase-, (3) N-acetylglutamat-synthetase-, (4) 
argininosuccinat-synthetase- and (5) arginino-succinat-lyase deficiency. As the incidence of 
these enzyme defects is low, valproic-acid encephalopathy very seldom has a hereditary 
cause. A high level of ammoniac can lead to hepatic necrosis in addition to encephalopathy. 
Hyperammonemia can be induced by the drugs depicted in table 2. Recent study data 
indicate that the hyperammonemia observed in patients under valproic-acid treatment is 
based on the direct inhibition of hepatic N-acetylglutamate synthase activity by valproyl-
CoA (Aires et al., 2011). Hyperammonemia can induce an encephalopathy by inhibiting the 
glutamate uptake by astrocytes, thus provoking neuronal damage and cerebral oedema 
(Blindauer et al., 1998). Moreover, elevated extracellular glutamate reduces the size of the 
astroctyes, thereby inhibiting their function. The reduced synthesis of glutathione causes the 
neurons and glia cells to become more vulnerable to oxidative stress (Verotti et al., 2002). 
Finally, the over-production of glutamine leads to a swelling of the astrocytes followed by 
cerebral oedema and even higher cerebral pressure (Noremberg, 1996).  
Drug Reference
5-Fluouracil Advani & Fakih et al., 2011
Acetazolamide Kim et al., 2007
Carbamazepine Adams et al., 2009
Haloperidol Rubenstein et al., 1990
Lamotrigine Fan et al., 2008
Primidone Katano et al., 2002
Valproate acid Aires et al., 2011
Zonisamide Shaikh et al., 2009
Table 2. Drugs inducing hyperammonemia 
An acute intermittent porphyria as one form of acute hepatic porphyria can present as a 
diffuse encephalopathy (Maramattom et al., 2005). Additionally, a mouse model has 
demonstrated that griseofulvin induces a hepatic porphyria characterized by psychiatric 
behavior sometimes observed in drug-induced encephalopathies (Satoh et al., 2008). 
Drugs such as barbiturates, bernegride, chloramphenicol, chlordiazepoxide, chloroquine, 
chlorpropamide, danazol, diazepam, ergot preparations, estrogens, ethanol excess, 
griseofulvin, halothane, hydantoins, imipramine, ketamine, meprobamate, methyldopa, 
methyprylon, methsuximide, nikethamide, oral contraceptives, pentazocine, phensuximide, 
phenylbutazone, progestogens, pyrazinamide, pyrazolone derivatives, sulfonamides, 
theophylline derivatives, tolbutamide, troxidone and valproic acid (Bonkowsky et al., 1982) 
have been reported to exacerbate acute porphyrias. These drugs should thus be 
administered with caution in patients with an encephalopathy associated with porphyria. A 
further mechanism leading to an encephalopathy based on an increase in neuronal P450 
CYP2E1 activity is induced by acetaminophen in an animal model (Posadas et al., 2010). 
Posadas et al. showed that acetoaminophen can result in a concentration-dependent 
neuronal apoptosis on rat cortical neurons through a mitochondrial-mediated mechanism 
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that includes cytochrome c release and caspase 3 activation (Posadas et al., 2010). 
Surprisingly, the neurotoxic action by acetoaminophen in rats is below those required to 
induce hepatotoxicity.  
3.4 Effects on cerebral receptors 
Effects on cerebral receptors play a important role as underlying pathomechanisms in drug-
induced encephalopathy. The neurotoxicty in metronidazole encephalopathy is based on the 
RNA (Bradley et al., 1977) and DNA binding of intermediate metabolites of metronidazole 
(Wright & Tyler, 2003), modulating inhibitory GABA receptors in the cerebellar and 
vestibular systems (Evans et al., 2003).  
Interaction with the GABA receptor plays a role in the intrinsic toxic effects of valproic acid 
encephalopathy (Miyazaki et al., 1988). Topiramate can induce a direct toxic effect on the 
central nervous system (CNS). Combined therapy with valproat acid produces this effect by 
reducing the metabolism of topiramate due to the interaction of valproic acid with the 
cytochrome-P450 effect. Gabapentin may cause a reversible encephalopathy clinically 
characterised by an asterixis. One candidate mechanism this encephalopathy is the agonistic 
interaction of gabapentin on cerebral GABA receptors in conjunction with increased 
inhibitory action (Fink et al., 2002). Cephalosporine-induced encephalopathy seems to 
involve GABA A receptor inhibition (Grill & Magati et al., 2008).  
3.5 Metabolic effects 
Severe diseases or malnutrition have a reduction in glucuron acid as a consequence. It is 
thus possible to inhibit the glucoronidation of valproate acid, resulting in a higher 
cumulative concentration of valproic acid, lamotrigine and oxcarbazepine in blood levels.  
3.6 Vasogenic and cytotoxic brain oedema 
Vasogenic and cytotoxic brain oedema as an underlying mechanism of a drug-induced 
encephalopathy is widespread. Metronidazole encephalopathy is probably caused by 
vasogenic and cytotoxic brain oedema. Most of the lesions in metronidazole encephalopathy 
correspond to areas of vasogenic oedema according to diffusion weighted imaging. Some 
lesions are located in the corpus callosum and correspond to cytotoxic oedema. Cytotoxic 
oedema is also a candidate mechanism in IVIG-induced encephalopathy. An intramyelinic 
oedema in the myelin sheath was observed in IVIG-induced encephalopathy (Wada et al., 
2005). Many drug-induced encephalopathies share in common a posterior reversible 
leukoencephalopathy syndrome (PRES) possibly due to vasogenic oedema. 
3.7 Posterior reversible leukoencephalopathy syndrome 
The PRES has been described after the intake of immunosuppressants such as tacrolimus, 
cyclosporine or in association with acute hypertensive encephalopathy and eclampsia 
(Hinchey et al., 1996). It is characterised by capillary-leak syndrome in the brain caused by 
hypertension, liquid retention, immunosuppressants, and chemotherapeutics affecting the 
vascular endothelium. Clinical symptoms are headache, vomiting, confusion, seizures, 
cortical blindness and other visual symptoms. Neuroimaging reveals bilateral signal 
alterations in the posterior white mater suggesting oedema.  
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Candidate Mechanism Drugs Reference
cytotoxic brain edema IVIG, metronidazole Kim et al., 2011; 
Wada et al., 2005 
effect on cerebral 
receptors 
methotrexate Sasazaki et al., 1992 
electrolytic disturbance theophylline Suarez Ortega et al., 1995 
hepatic enzyme 
interactions 
valproic acid Bauer & Elger,1993 
hypoalbuminia ifofosfamide Sweiss et al., 2008
metabolic effects lamotrigine, oxcarbazepine, 
valproic acid, 
Bauer & Elger 1993,  
Hennessy & Miles, 1996 
neurotoxic effect IVIG Wada et al., 2005
posterior reversible
leukoencephalopathy 
syndrome 
dexametha-sone, 
tacrolimus,  
Kim et al., 2011; 
Irvin et al., 2007; 
Zhang, 2011 
vasogenic brain edema metronidazole Kim et al., 2011
Table 3. Drug-induced encephalopathy-pathophysiological mechanisms 
4. Pathological studies 
Mild gliosis of the white matter and ischemic lesions in the temporal area were observed in 
a patient’s postmortem analysis (Steeghs et al., 2003). Pathological-anatomic studies showed 
changes in the cerebellum and temporal lobe of predominantly the pyramidal and purkinje 
cells in rats after chronic administration of valproate acid (Sobaniek-Lotowska, 2003). Those 
studies reported damage to the hippocampal astrocytes and neocortex. All these 
abnormalities seemed to disappear three months after discontinuation of the drug.  
5. Genetic susceptibility 
A further factor contributing to the development of a drug-induced encephalopathy is genetic 
susceptibility. The individual´s genetic patrimony including ethnicity and gender influences 
the susceptibility to the risk of a drug-induced encephalopathy. Any genetic polymorphism 
may influence the metabolism, excretion or action of the drug depending on single or multiple 
genes or by changes in gene expression (Dodd et al., 2004). For instance, some mutations can 
promote development of an encephalopathy, i.e. a mutation in ETHE1, a mitochondrial matrix 
sulphur dioxygenase causing an ethlymalonic encephalopathy (Viscomi et al., 2010). In a 
patient with the rare missense variant methionine synthetase c.2756A>G (D919G), a 
methotrexate encephalopathy was observed probably due to a modified effect of methotrexate 
on homocysteine metabolism (Linnebank et al., 2007). A recent clinical study showed that the 
genetic polymorphism of the human thymidylate synthetase gene contributes to 5-
fluorouracil-associated hyperammonemic encephalopathy. A GABA A receptor modification 
caused by knockout of the taurine transporter resulted in striatal disinhibition in mice. This 
animal study demonstrates that a genetic defect ending up in a lack of taurine partly explains 
the pathophysiology of a hepatic encephalopathy (Sergeeva et al., 2007). Mitochondrial 
dysfunction underlies different types of encephalopathy, for example, mitochondrial 
myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS). As an example, 
the mutation of mitochondrial DNA (mtDNA) G13513A encoding the ND5 subunit of 
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respiratory chain complex 1 causes mitochondrial encephalopathy with lactic acidosis (Wang 
et al. 2008). Therefore, supplementation with the mitochondrial respiratory chain cofactor 
coenzyme Q10 has been demonstrated to advance recuperation following heroin-induced 
encephalopathy (Gacouin et al., 2003).  
6. Epidemiology 
The epidemiology of ifofosfamide encephalopathy is well known. Ifofosfamide 
encephalopathy occurred in 31.2% of patients with soft tissue and bone sarcomas (17/61) 
treated with ifofosfamide, and in 13.6% of ifofosfamide treatment courses. A history of 
cisplatin was identified as a potential risk factor for the development of an ifofosfamide-
induced encephalopathy (Tajino et al., 2010). Furthermore, a dose of ifofosfamide at >9g/m2 
is a further risk factor of ifofosfamide-induced encephalopathy (Tajino et al., 2010). In other 
previous studies, risk factors such as large tumors in the female pelvic cavity (Meanwell et 
al., 1986), poor performance status (Antman et al., 1989), hypoalbuminemia (Merimsky et 
al., 1992), high serum creatinine level (Antmann et al., 1990) and low iron bicarbonate level 
(Antmann et al., 1989) were identified as risk factors for ifofosfamide-induced 
encephalopathy. It remains controversial as to whether there are risk factors of ifofosfamide-
induced encephalopathy, as another study showed no risk factors associated with this 
encephalopathy and that each patient has his own predisposition (Rieger et al. 2004). 
Alcoholism was identified as a risk factor in linezolide-induced encephalopathy (Fletcher et 
al., 2010). Renal failure and previous central nervous system disease may predispose to 
ceftriaxone- and cefepime-induced encephalopathy (Roncon- Albuquerque et al., 2009; 
Garces et al. 2008). Dialysis may be a risk factor in isoniazide-induced encephalopathy 
(Cheung et al. 1993). There are common risk factors affecting the neuronal health for 
different types of drug-induced encephalopathies such as environmental toxins, infectious 
diseases, traumatic events, brain tumors, brain ischemia, age (state of health, disease), 
nutritional deficiencies and intolerances, and even poverty (Virmani et al. 2010).  
In conclusion, not everyone develops an encephalopathy after taking a certain drug, but 
those individuals who are at risk (see above) - although the extent and nature of the risk are 
often unknown - may be more apt to develop an encephalopathy.  
Patients with metronidazole encephalopathy showed a mean age of 61 years (49-71 years) 
(Kim et al., 2007), whereas those with clarithromycin encephalopathy exhibited an average 
age of 51 years (19-87 years) (Bandetti di Poggio et al., 2011). These data are based on case 
series, and there are no long-term clinical studies addressing the epidemiology of drug-
induced encephalopathies. In a cohort study of 19 patients, 8 patients (42%) developed an 
ifofosfamide induced encephalopathy (Sweiss et al. 2008). The exact prevalence of a drug-
induced encephalopathy is unknown, as case series with calculated epidemiologic data are 
rare. Furthermore, there are no studies larger in scale examining the specific age of a drug-
induced encephalopathy. The average age for valproic-acid encephalopathy was 38.6 years 
in a long-term study (Gerstner et al. 2007).  
Toxic encephalopathies are accompanied by high blood levels of the suspected drug, 
whereas drug-induced encephalopathies often reveal therapeutic blood levels of the drug. 
Thus we know of no dose-dependent effect of drugs that induce an encephalopathy. The 
symptoms can develop from within hours until a month after taking the drug.  
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7. Basic clinical features 
The clinical spectrum of symptoms can result in slight disturbances of the mental state up to 
severely damaged consciousness (table 4). Transient acute encephalopathy has been 
observed in 3-15% of cancer patients after methotrexate therapy (Rubnitz et al. 1998). 
Chronic encephalopathy develops slowly, may progress, and can permanently impair 
neurological function. A drug-induced encephalopathy may reveal a varied spectrum of 
psychiatric symptoms, i.e. hallucinations (Sorafenib; Dogan et al., 2010), psychotic state 
(vigabatrine; Garcia-Pastore et al., 2000), depression (sodium valproate, Connacher et al., 
1987) and neuropsychologic symptoms like reduced psychomotor speed and impaired 
working memory (levetiracetame, valproic acid; Bauer et al., 2008). The development of 
psychiatric symptoms may be acute, subacute or chronic. 
Clinics Drugs Reference 
abnormal sensation metronidazole Wada et al., 2005 
aggravation of preexisting 
neurological deficits 
carbamazepine, gabapentine, 
levetiracetame, lamotrigine, 
oxcarbazepine, primidone, 
topiramate 
Bauer, 2008; Hennessy & 
Miles, 1996, Horvath et al., 
2005; Katano et al., 2002; 
Latour et al., 2004; 
Siniscalchi et al., 2004; 
Sechi et al., 2004  
altered consciousness, 
concentration 
capecitabine, gabapentine, 
IVIG, lithium, valproic acid  
Bauer & Elger 1993; Fantini 
et al., 2010; Katano et al., 
2002; Sechi et al., 2004 
anisocoria, diplopia dexamethasone Irvin et al., 2007 
aphasia carbamazepine, topiramate Horvath et al., 2005, Latour 
et al., 2004 
ataxia, apraxia capecitabine, carbamazepine, 
phenytoine, topiramate, 
valproic acid 
Fantini et al., 2010, Horvath 
et al., 2005 
choreiform movements, 
athetosis 
tiagabine, trimetazidine, Sivet et al., 2008;  
Tombini et al., 2006 
delirium, coma carmofur Kuzuhara et al., 1987 
dementia, memory loss carbamazepine, carmofur,  
gabapentine, levetiracetame  
Bauer, 2008; Horvath et al., 
2005, Kuzuhara et al., 1987; 
Sechi et al., 2004  
dysathria metronidazole, lithium, 
tacrolimus,  
Smith et al., 2003;  
Wada et al., 2005, 
gait disturbance carmofur, sorafenib, 
trimetazidine, 
Dogan et al., 2010; 
Kuzuhara et al., 1987; Sivet 
et al., 2008 
headache paclitaxel Perry & Warner, 1996 
myoclonias carbamazepine, 
levetiracetame, odansetrone,  
vigabatrine, lithium 
Bauer, 2008; Garcia-Pastor 
et al., 2000; Horvath et al., 
2005, Ritter et al., 2003; 
Smith et al., 2003 
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oculogyric crisis, 
oromandibular and 
 limb dystonia 
odansetrone Ritter et al., 2003 
parkinsonism carbamazepine Horvath et al., 2005 
psychiatric symptoms valproic acid, sorafenib, 
levetiracetame, vigabatrine 
Dogan et al.2010; Garcia-
Pastor et al., 2000;  
Bauer, 2008
ptosis dexamethasone Irvin et al., 2007 
seizures cisplatin, cyclosporine, 
gadolinium levetiracetame, 
valproic acid, vigabatrine  
Bauer, 2008; Bauer & Elger, 
1993, Dzudie et al., 2009; 
Garcia-Pastor et al., 2000; 
Kapoor et al., 2010; Steeghs 
et al., 2003;
sleep disturbance, 
hypersomnia, insomnia 
capecitabine, carbamazepine, 
topiramate 
Cheung et al., 2005, Fantini 
et al., 2010, Horvath et al., 
2005, Cheung et al., 2005 
stupor, agitated state morphine Eran & Barak, , 2009 
tremor tacrolimus Kim et al., 2011 
vertigo sorafenib, valproic acid Bauer & Elger, 1993; Dogan 
et al., 2010
visual symptoms, 
nystagmus 
metronidazole, phenytoine, 
primidone, trimetazidine, 
sorafenib, topiramate 
Wada et al., 2005; 
Dogan et al., 2010;  
Engel, 1971, 
Katano et al., 2002,  
Latour et al., 2004;  
Sivet et al., 2008;  
vomiting, nausea valproic acid Bauer & Elger, 1993 
Table 4. Drug-induced encephalopathy- Clinics 
8. Diagnostics 
8.1 Electrophysiologic studies 
EEG has often revealed signs of encephalopathy. The main characteristics are a diffuse, 
unusually mild to heavy general changes (Horvath et al., 2005, Tombini et al., 2006). 
Triphasic waves with intermittent frontal delta activity are sometimes observed (Gallmetzer 
et al., 2004; Rancon-Albuquerque et al., 2009). Focal and generalised slow waves, and 
generalised or focal epileptic spike-wave complexes have also been seen. Once the 
responsible drug is discontinued, the encephalopathy with general slowing and epileptic 
discharges resolve after days or weeks, sometimes after months (Bauer & Elger, 1993; Latour 
et al., 2004).  
8.2 Laboratory investigations 
The effective concentration of the drug in sera is often within the normal range in patients 
with valproic acid-induced encephalopathy (Bauer & Elger, 1993), whereas higher 
concentration of the drugs were noted in carbamazepine (Neumann et al. 1994) and 
lamotrigine encephalopathy (Hennesy & Miles, 1996). When clinical signs and symptoms of 
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a drug-induced encephalopathy are present, relevant clinical routine tests for natremia, 
ammonemia or glycemia should always be performed to identify the reason for the 
encephalopathy and develop a treatment strategy. A hypoglycemic encephalopathy can be 
detected by measuring the blood glucose level, thereby differentiating it from drug-induced 
encephalopathies. The clinical spectrum of hypoglycemic encephalopathy ranges from 
simple neurological deficits and mental changes to severe coma and death (Lo et al., 2006). 
A specific lesion pattern is frequently detected in hypoglycemic encephalopathy, often 
affecting the cerebral cortex, basal ganglia, hippocampus, splenium and bilateral internal 
capsula (Aoki et al., 2004; Chan et al., 2003; Terakawa et al., 2007; Cho et al., 2006). This 
selective vulnerability in hypoglycemic encephalopathy may be associated with the extent to 
which the metabolism necessary to conserve the function of brain structures and neuronal 
integrity has been compromised (Lee et al., 2011).  
8.3 Imaging patterns  
Cerebral atrophy has been observed in valproic-acid encephalopathy, especially in chronic 
encephalopathy as some authors have described in cranial computertomography (CT) and 
magnetic resonance imaging (MRI) (Baganz et al., 1994; Papazian et al., 1995). Lacunar 
lesions were found in gabapentin-induced encephalopathy (Sechi et al., 2004). 
Metronidazole-induced encephalopathy induced bilateral symmetric T2-hyperintense 
lesions in the cerebellar dentate nucleus, midbrain, dorsal pons, medulla, and splenium of 
the corpus callosum. Except for the corpus callosum, all lesions were irreversible. The 
lesions are often bilateral and symmetric. High signal intensity in T2-weighted images 
appeared, but the signal alterations did not demonstrate contrast enhancement and were 
reversible after drug discontinuation. Dexamethasone encephalopathy in MRI resulted in 
diffuse cortical and subcortical white matter lesions in symmetric bilateral distribution 
involving predominantly occipital areas, the cerebellum and focal areas of bilateral thalami 
not evident in the T1-weighted images characteristic of PRES. In cyclosporine-induced 
encephalopathy, the lesions show vasogenic oedema apparently in diffusion coefficient 
maps (Bartynski et al., 2007). Some imaging pattern are shown in table 5. 
Anatomic lesion pattern Drugs Reference 
bilateral temporal 
periventricular white-matter 
lesions  
sulfasalazine Mut et al., 2008 
centrum semi-oval atrophy tacrolimus Kim et al., 2011 
cerebellum metronidazole Kim et al., 2011 
corpus callosum metronidazole Kim et al., 2011 
cortical and subcortical parietal, 
occipital and frontal white 
matter lesions  
dexamethasone, IVIG Irvin et al., 2007; Wada et 
al., 2005 
deep white matter lesions capecitabine, paclitaxel Fantini et al., 2010; Perry & 
Warner, 1996 
midbrain, pons, medulla lesions metronidazole Kim et al., 2011 
Table 5. Neuroimaging of drug-induced encephalopathies 
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9. Differential diagnosis 
The most important differential diagnosis of metronidazole-induced encephalopathy is 
Wernicke encephalopathy. In the early stages of the disease, the two entities may be 
confounded because they can produce similar clinical features. In metronidazole-induced 
encephalopathy (unlike Wernicke encephalopathy), lesions of cerebellar dentate nuclei are 
supported by pathological studies (Troncoso et al., 1981). Further differential diagnoses are 
acute infectious encephalitis and demyelinating disease including Marchiafava-Bignami 
disease. Other types of encephalopathies must be differentiated from drug-induced 
encephalopathies such as hepatic, heavy metal, uremic, septic, and mitochondrial 
encephalopathy.  
10. Therapeutic options 
Therapy consists in the immediate discontinuation of the suspected drug when first signs 
of encephalopathy appear. A complete reversal of symptoms should take place soon after 
drug discontinuation. The atrophy in valproate-induced encephalopathy can also be 
reversed in individual cases. The administration of L-carnitine makes therapeutic sense in 
cases of carnitine deficiency (Kelley, 1994). Intravenous carnitine was recently shown to 
be useful in the treating hyperammonemic encephalopathy (BØhmer & Hoymork, 2010). 
Moreover, the treatment of a valproate-induced encephalopathy via haemodialysis has 
succeeded (Tsai & Chen, 2008). Short-term hemodialysis often helps to reverse the 
symptoms in cefepime encephalopathy (Lin et al., 2011). Drug-induced encephalopathy 
often has a good prognosis. Methylen blue is an therapeutic option for an ifosfamide-
induced encephalopathy (Patel, 2006). A drug-induced encephalopathy can sometimes be 
prevented by adjusting the dosage and monitoring serum concentrations of the suspected 
drug. Normally the blood level of the suspected drug is within the therapeutic range, so 
that treating an overdose would make no sense. Only in particular situations are certain 
measures to treat overdoses necessary, i.e. gastric lavage, activated charcoal, 
hemodialysis, hyperhydration or forced diuresis.  
11. Conclusions 
Several drugs can induce drug-induced encephalopathies. They seldom occur in clinical 
practice, but are important pharmacological side effects. Drug-induced encephalopathies are 
a key differential diagnosis when a disturbance of the consciousness is initially unclear. The 
effective levels of the drug in the blood often fall within the reference and not in the toxic 
range. Effective therapy consists in immediately discontinuing the drug.  
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